Ani Pharmaceuticals (ANIP) Deferred Taxes (2014 - 2026)

Ani Pharmaceuticals (ANIP) has 13 years of Deferred Taxes data on file, last reported at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Deferred Taxes rose 174.34% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $20.1 million (up 170.9% YoY), and the FY2025 full-year result was $14.2 million, up 164.97% from the prior year.
• Deferred Taxes rose to $2.5 million in Q1 2026, from $2.4 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $18.8 million in Q3 2025 to a low of -$17.5 million in Q4 2024.
• A 5-year average of -$1.9 million and a median of -$2.2 million in 2022 frame the typical range for Deferred Taxes.
• Across the five-year window, Deferred Taxes slumped 2575.27% in 2022 and soared 436.44% in 2025, its largest moves.
• Tracing ANIP's Deferred Taxes over 5 years: stood at -$1.6 million in 2022, then tumbled by 413.6% to -$8.3 million in 2023, then slumped by 110.04% to -$17.5 million in 2024, then surged by 113.44% to $2.4 million in 2025, then gained by 6.75% to $2.5 million in 2026.
• Business Quant data shows ANIP's Deferred Taxes at $2.5 million in Q1 2026, $2.4 million in Q4 2025, and $18.8 million in Q3 2025.